CSBR vs. JSPR, VALN, CCCC, FDMT, ITOS, ENGN, ATYR, OCGN, ARTV, and IKT
Should you be buying Champions Oncology stock or one of its competitors? The main competitors of Champions Oncology include Jasper Therapeutics (JSPR), Valneva (VALN), C4 Therapeutics (CCCC), 4D Molecular Therapeutics (FDMT), iTeos Therapeutics (ITOS), enGene (ENGN), Atyr PHARMA (ATYR), Ocugen (OCGN), Artiva Biotherapeutics (ARTV), and Inhibikase Therapeutics (IKT). These companies are all part of the "biological products, except diagnostic" industry.
Champions Oncology vs.
Jasper Therapeutics (NASDAQ:JSPR) and Champions Oncology (NASDAQ:CSBR) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, community ranking, valuation, analyst recommendations, risk, media sentiment, institutional ownership, earnings and profitability.
Jasper Therapeutics has a beta of 2.18, indicating that its stock price is 118% more volatile than the S&P 500. Comparatively, Champions Oncology has a beta of 0.52, indicating that its stock price is 48% less volatile than the S&P 500.
Champions Oncology has higher revenue and earnings than Jasper Therapeutics. Champions Oncology is trading at a lower price-to-earnings ratio than Jasper Therapeutics, indicating that it is currently the more affordable of the two stocks.
79.8% of Jasper Therapeutics shares are owned by institutional investors. Comparatively, 41.3% of Champions Oncology shares are owned by institutional investors. 2.7% of Jasper Therapeutics shares are owned by company insiders. Comparatively, 47.0% of Champions Oncology shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
In the previous week, Jasper Therapeutics had 1 more articles in the media than Champions Oncology. MarketBeat recorded 2 mentions for Jasper Therapeutics and 1 mentions for Champions Oncology. Jasper Therapeutics' average media sentiment score of 1.79 beat Champions Oncology's score of 1.04 indicating that Jasper Therapeutics is being referred to more favorably in the media.
Champions Oncology received 111 more outperform votes than Jasper Therapeutics when rated by MarketBeat users. However, 88.89% of users gave Jasper Therapeutics an outperform vote while only 60.40% of users gave Champions Oncology an outperform vote.
Jasper Therapeutics presently has a consensus target price of $73.38, indicating a potential upside of 240.17%. Champions Oncology has a consensus target price of $8.00, indicating a potential upside of 6.60%. Given Jasper Therapeutics' higher probable upside, equities research analysts clearly believe Jasper Therapeutics is more favorable than Champions Oncology.
Jasper Therapeutics has a net margin of 0.00% compared to Champions Oncology's net margin of -1.12%. Champions Oncology's return on equity of 0.00% beat Jasper Therapeutics' return on equity.
Summary
Jasper Therapeutics beats Champions Oncology on 9 of the 16 factors compared between the two stocks.
Get Champions Oncology News Delivered to You Automatically
Sign up to receive the latest news and ratings for CSBR and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Champions Oncology Competitors List
Related Companies and Tools
This page (NASDAQ:CSBR) was last updated on 12/21/2024 by MarketBeat.com Staff
Free CSBR Stock Alerts